Research Analysts’ Weekly Ratings Updates for Biogen (BIIB)

Biogen (NASDAQ: BIIB) recently received a number of ratings updates from brokerages and research firms:

• 11/2/2026 – Biogen had its price target raised by Guggenheim from $280.00 to $300.00. They now have a “buy” rating on the stock.
• 11/2/2026 – Biogen had its price target raised by HC Wainwright from $251.00 to $270.00. They now have a “buy” rating on the stock.
• 10/31/2026 – Biogen was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 10/29/2026 – Biogen was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 10/29/2026 – Biogen had its price target raised by Royal Bank Of Canada from $256.00 to $272.00. They now have an “outperform” rating on the stock.
• 10/29/2026 – Biogen had its price target raised by Wedbush from $212.00 to $225.00. They now have a “neutral” rating on the stock.
• 10/29/2026 – Biogen had its price target raised by UBS Group from $270.00 to $300.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Biogen had its price target raised by Canaccord Genuity Group from $248.00 to $272.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Biogen had its price target raised by Morgan Stanley from $231.00 to $238.00. They now have an “equal weight” rating on the stock.
• 10/29/2026 – Biogen had its price target raised by TD Cowen from $250.00 to $260.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Biogen had its “buy” rating reaffirmed by Truist Financial. They now have a $260.00 price target on the stock, up from $235.00.
• 10/29/2026 – Biogen was upgraded by Argus from “hold” to “buy”. They now have a $280.00 price target on the stock.
• 10/29/2026 – Biogen had its price target raised by Needham & Company LLC from $256.00 to $290.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Biogen had its price target raised by Robert W. Baird from $250.00 to $290.00. They now have an “outperform” rating on the stock.
• 10/28/2026 – Biogen had its “neutral” rating reaffirmed by Citigroup.
• 10/28/2026 – Biogen had its price target raised by Barclays from $200.00 to $230.00. They now have an “equal weight” rating on the stock.
• 10/22/2026 – Biogen had its price target raised by Bank of America from $219.00 to $244.00. They now have a “neutral” rating on the stock.
• 10/21/2026 – Biogen had its price target raised by TD Cowen from $225.00 to $250.00. They now have a “buy” rating on the stock.
• 10/20/2026 – Biogen had its price target raised by Wells Fargo & Company from $250.00 to $310.00. They now have an “overweight” rating on the stock.
• 10/12/2026 – Biogen had its “market perform” rating reaffirmed by BMO Capital Markets. They now have a $220.00 price target on the stock.
• 10/12/2026 – Biogen was upgraded by Seaport Research Partners to “outperform”.
• 10/12/2026 – Biogen was upgraded by JPMorgan Chase & Co. from “neutral” to “overweight”. They now have a $300.00 price target on the stock, up from $210.00.
• 10/9/2026 – Biogen had its price target raised by UBS Group from $240.00 to $270.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Biogen had its price target lowered by Royal Bank Of Canada from $260.00 to $256.00. They now have an “outperform” rating on the stock.
• 9/24/2026 – Biogen was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 9/10/2026 – Biogen was given a new $242.00 price target by Stifel Nicolaus.
• 9/10/2026 – Biogen had its price target raised by HSBC from $165.00 to $175.00. They now have a “reduce” rating on the stock.

Biogen Stock Performance

NASDAQ BIIB opened at $249.01 on Tuesday. The company has a fifty day moving average of $227.72 and a two-hundred day moving average of $201.40. The company has a market capitalization of $36.79 billion, a PE ratio of 106.41, a P/E/G ratio of 2.87 and a beta of 0.09. Biogen Inc. has a 1 year low of $148.51 and a 1 year high of $258.78. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The business had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.63 billion. During the same quarter in the previous year, the firm earned $4.81 earnings per share. The business’s revenue was up 10.6% compared to the same quarter last year. As a group, analysts expect that Biogen Inc. will post 12.44 earnings per share for the current year.

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.